AxioMx, a biotech company, has raised about $2 million in venture debt, according to the company’s new filing with the Securities and Exchange Commission. Four separate investors participated in the bid
AxioMx uses knowledge gained from the last 15 years of human genome sequence to produce highly specific recombinant antibodies to human proteome. The current antibody development paradigm is too slow and does not always result in consistent, renewable and quality antibodies. By proprietary advances in traditional phage display antibody library design, phage display screening and affinity maturation technologies, we quickly generate antibodies to meet the required binding and specificity criteria. At AxioMx, we believe that our platform will lead to the broad adoption of recombinant antibody use in research and diagnostic applications.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/AxioMx/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
